We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

STRATEC Biomedical AG (SBS) NPV

Sell:€34.30 Buy:€34.95 Change: No change
Market closed |  Prices as at close on 22 January 2025 | Switch to live prices |
Sell:€34.30
Buy:€34.95
Change: No change
Market closed |  Prices as at close on 22 January 2025 | Switch to live prices |
Sell:€34.30
Buy:€34.95
Change: No change
Market closed |  Prices as at close on 22 January 2025 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Stratec SE is a Germany-based company. The Company is engaged in development and manufacture of analyzer systems, and it is also performing and managing administrative and organizational tasks for laboratory markets. Stratec is providing automation solutions and instrumentation of biochemical processes using hardware and software for in-vitro diagnostics and life science companies. It also developing and integrating instrumentation, complex consumables and software by covering virtually the entire value chain for specification, design, manufacture and approval of complex analyzer system solutions.

Contact details

Address:
Gewerbestr. 37
BIRKENFELD
75217
Germany
Telephone:
+49 (7082) 79160
Website:
https://www.stratec.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SBS
ISIN:
DE000STRA555
Market cap:
€413.37 million
Shares in issue:
12.16 million
Sector:
Health Care Equipment
Exchange:
Frankfurt Stock Exchange
Country:
Germany
Currency:
Euro
Indices:
n/a

Key personnel

  • Georg Heni
    Independent Chairman of the Supervisory Board
  • Marcus Wolfinger
    Chairman of the Management Board, Chief Executive Officer
  • Frank Hiller
    Independent Deputy Chairman of the Supervisory Board
  • Oliver Albrecht
    Interim Chief Financial Officer, Member of the Management Board
  • Georg Bauer
    Director - Sales, Member of the Management Board
  • Claus Vielsack
    Member of the Management Board, Director - Product Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.